Warning! GuruFocus detected
1 Severe warning sign
with MEIP.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
MEI Pharma Inc
NAICS : 325412
SIC : 2834
ISIN : US55279B2025
Description
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.04 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.53 | |||||
| Debt-to-EBITDA | -0.4 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 17.3 | |||||
| 3-Year FCF Growth Rate | -9.9 | |||||
| 3-Year Book Growth Rate | -17.4 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 15.22 | |||||
| 9-Day RSI | 22.46 | |||||
| 14-Day RSI | 26.67 | |||||
| 3-1 Month Momentum % | -8.21 | |||||
| 6-1 Month Momentum % | -10.55 | |||||
| 12-1 Month Momentum % | -39.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.66 | |||||
| Quick Ratio | 10.66 | |||||
| Cash Ratio | 10.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.8 | |||||
| Shareholder Yield % | 6.2 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -55.2 | |||||
| ROE % | -100.3 | |||||
| ROA % | -78.54 | |||||
| ROIC % | -396.13 | |||||
| 3-Year ROIIC % | -579.43 | |||||
| ROC (Joel Greenblatt) % | -394.07 | |||||
| ROCE % | -70.03 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.22 | |||||
| PB Ratio | 0.6 | |||||
| Price-to-Tangible-Book | 0.6 | |||||
| EV-to-EBIT | 0.81 | |||||
| EV-to-EBITDA | 0.83 | |||||
| EV-to-Revenue | -0.37 | |||||
| EV-to-Forward-Revenue | 26.46 | |||||
| EV-to-FCF | 0.67 | |||||
| Price-to-GF-Value | 0.22 | |||||
| Price-to-Net-Current-Asset-Value | 0.6 | |||||
| Price-to-Net-Cash | 0.62 | |||||
| Earnings Yield (Greenblatt) % | 123.46 | |||||
| FCF Yield % | -270.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MEIP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MEI Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 65.297 | ||
| EPS (TTM) ($) | -5.73 | ||
| Beta | 0.36 | ||
| 3-Year Sharpe Ratio | -0.82 | ||
| 3-Year Sortino Ratio | -1 | ||
| Volatility % | 51.15 | ||
| 14-Day RSI | 26.67 | ||
| 14-Day ATR ($) | 0.097967 | ||
| 20-Day SMA ($) | 2.3087 | ||
| 12-1 Month Momentum % | -39.26 | ||
| 52-Week Range ($) | 1.9 - 4.1 | ||
| Shares Outstanding (Mil) | 6.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MEI Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MEI Pharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
MEI Pharma Inc Frequently Asked Questions
What is MEI Pharma Inc(MEIP)'s stock price today?
The current price of MEIP is $2.00. The 52 week high of MEIP is $4.10 and 52 week low is $1.90.
When is next earnings date of MEI Pharma Inc(MEIP)?
The next earnings date of MEI Pharma Inc(MEIP) is 2025-05-09 Est..
Does MEI Pharma Inc(MEIP) pay dividends? If so, how much?
MEI Pharma Inc(MEIP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers